S&P 500   3,236.50 (-2.50%)
DOW   26,805.31 (-3.08%)
QQQ   263.67 (-1.20%)
AAPL   106.92 (+0.07%)
MSFT   199.57 (-0.41%)
FB   246.80 (-2.27%)
GOOGL   1,423.32 (-1.91%)
AMZN   2,891.57 (-2.14%)
NVDA   490.49 (+0.60%)
TSLA   440.96 (-0.27%)
BABA   270.89 (-0.56%)
CGC   15.57 (-4.83%)
GE   6.25 (-9.16%)
MU   48.87 (-3.69%)
AMD   76.46 (+2.04%)
T   28.31 (-2.14%)
F   6.86 (-5.12%)
ACB   6.34 (-2.91%)
GILD   63.61 (-2.21%)
NFLX   478.96 (+1.92%)
DIS   124.37 (-3.31%)
BAC   24.11 (-4.36%)
BA   156.61 (-2.81%)
S&P 500   3,236.50 (-2.50%)
DOW   26,805.31 (-3.08%)
QQQ   263.67 (-1.20%)
AAPL   106.92 (+0.07%)
MSFT   199.57 (-0.41%)
FB   246.80 (-2.27%)
GOOGL   1,423.32 (-1.91%)
AMZN   2,891.57 (-2.14%)
NVDA   490.49 (+0.60%)
TSLA   440.96 (-0.27%)
BABA   270.89 (-0.56%)
CGC   15.57 (-4.83%)
GE   6.25 (-9.16%)
MU   48.87 (-3.69%)
AMD   76.46 (+2.04%)
T   28.31 (-2.14%)
F   6.86 (-5.12%)
ACB   6.34 (-2.91%)
GILD   63.61 (-2.21%)
NFLX   478.96 (+1.92%)
DIS   124.37 (-3.31%)
BAC   24.11 (-4.36%)
BA   156.61 (-2.81%)
S&P 500   3,236.50 (-2.50%)
DOW   26,805.31 (-3.08%)
QQQ   263.67 (-1.20%)
AAPL   106.92 (+0.07%)
MSFT   199.57 (-0.41%)
FB   246.80 (-2.27%)
GOOGL   1,423.32 (-1.91%)
AMZN   2,891.57 (-2.14%)
NVDA   490.49 (+0.60%)
TSLA   440.96 (-0.27%)
BABA   270.89 (-0.56%)
CGC   15.57 (-4.83%)
GE   6.25 (-9.16%)
MU   48.87 (-3.69%)
AMD   76.46 (+2.04%)
T   28.31 (-2.14%)
F   6.86 (-5.12%)
ACB   6.34 (-2.91%)
GILD   63.61 (-2.21%)
NFLX   478.96 (+1.92%)
DIS   124.37 (-3.31%)
BAC   24.11 (-4.36%)
BA   156.61 (-2.81%)
S&P 500   3,236.50 (-2.50%)
DOW   26,805.31 (-3.08%)
QQQ   263.67 (-1.20%)
AAPL   106.92 (+0.07%)
MSFT   199.57 (-0.41%)
FB   246.80 (-2.27%)
GOOGL   1,423.32 (-1.91%)
AMZN   2,891.57 (-2.14%)
NVDA   490.49 (+0.60%)
TSLA   440.96 (-0.27%)
BABA   270.89 (-0.56%)
CGC   15.57 (-4.83%)
GE   6.25 (-9.16%)
MU   48.87 (-3.69%)
AMD   76.46 (+2.04%)
T   28.31 (-2.14%)
F   6.86 (-5.12%)
ACB   6.34 (-2.91%)
GILD   63.61 (-2.21%)
NFLX   478.96 (+1.92%)
DIS   124.37 (-3.31%)
BAC   24.11 (-4.36%)
BA   156.61 (-2.81%)
Log in
NASDAQ:ADXS

Advaxis Stock Forecast, Price & News

$0.41
-0.03 (-7.17 %)
(As of 09/21/2020 02:15 PM ET)
Add
Compare
Today's Range
$0.41
Now: $0.41
$0.43
50-Day Range
$0.43
MA: $0.50
$0.60
52-Week Range
$0.21
Now: $0.41
$1.48
Volume37,656 shs
Average Volume2.71 million shs
Market Capitalization$27.36 million
P/E RatioN/A
Dividend YieldN/A
Beta3.48
Advaxis, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with OS Therapies LLC; Amgen Inc.; Especificos Stendhal SA de CV; Merck & Co., Inc.; MedImmune/AstraZeneca; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Read More
Advaxis logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.61 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADXS
CUSIPN/A
Phone609-452-9813

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20.88 million
Book Value$0.48 per share

Profitability

Net Income$-16,610,000.00
Net Margins-13,144.62%

Miscellaneous

Employees58
Market Cap$27.36 million
Next Earnings Date12/18/2020 (Estimated)
OptionableOptionable
$0.41
-0.03 (-7.17 %)
(As of 09/21/2020 02:15 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ADXS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Advaxis (NASDAQ:ADXS) Frequently Asked Questions

How has Advaxis' stock price been impacted by COVID-19 (Coronavirus)?

Advaxis' stock was trading at $0.6666 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ADXS shares have decreased by 38.0% and is now trading at $0.4131.
View which stocks have been most impacted by COVID-19
.

When is Advaxis' next earnings date?

Advaxis is scheduled to release its next quarterly earnings announcement on Friday, December 18th 2020.
View our earnings forecast for Advaxis
.

How were Advaxis' earnings last quarter?

Advaxis, Inc. (NASDAQ:ADXS) issued its earnings results on Thursday, September, 10th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.06. Advaxis had a negative net margin of 13,144.62% and a negative return on equity of 81.49%.
View Advaxis' earnings history
.

Who are some of Advaxis' key competitors?

What other stocks do shareholders of Advaxis own?

Who are Advaxis' key executives?

Advaxis' management team includes the following people:
  • Mr. Kenneth A. Berlin J.D., Pres, CEO & Director (Age 55)
  • Ms. Molly Henderson CPA, CPA, MBA, Exec. VP, CFO & Corp. Sec. (Age 48)
  • Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 59)
  • Mr. Anthony A. Lombardo, Exec. Officer (Age 70)
  • Dr. Andres A. Gutierrez, Exec. VP & Chief Medical Officer (Age 58)

What is Advaxis' stock symbol?

Advaxis trades on the NASDAQ under the ticker symbol "ADXS."

Who are Advaxis' major shareholders?

Advaxis' stock is owned by many different retail and institutional investors. Top institutional shareholders include Bridgeway Capital Management Inc. (0.41%) and Virtu Financial LLC (0.27%). Company insiders that own Advaxis stock include Robert Petit and Roni Appel.
View institutional ownership trends for Advaxis
.

Which major investors are buying Advaxis stock?

ADXS stock was purchased by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., and Virtu Financial LLC.
View insider buying and selling activity for Advaxis
.

How do I buy shares of Advaxis?

Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Advaxis' stock price today?

One share of ADXS stock can currently be purchased for approximately $0.41.

How big of a company is Advaxis?

Advaxis has a market capitalization of $27.36 million and generates $20.88 million in revenue each year. Advaxis employs 58 workers across the globe.

What is Advaxis' official website?

The official website for Advaxis is www.advaxis.com.

How can I contact Advaxis?

Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.